References
- Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr. Hypertens. Rep. (5), 408–417 (2003).
- Yusuf S, Sleight P, Pogue J et al.; for The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med.342, 145–153 (2000).
- Fox KM, The European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease [EUROPA] Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet362, 782–788 (2003).
- Verma S, Gupta M, Holmes DT et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur. Heart J.32(17), 2135–2142 (2011).
- Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II–renin relationships to evaluate efficacy of converting enzyme blockade. J. Cardiovasc. Pharmacol.4(6), 966–972 (1982).
- Van Den Meiracker AH, Manintveld AJ, Admiraal PH et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens.10, 803–812 (1992).
- Brewster U, Perazella MA. The renin–angiotensin–aldosterone system and the kidney: effects on kidney disease. Am. J. Med.116, 236–272 (2004).
- Unger T, Sandmann S. Angiotensin receptor blocker selectivity at the AT1- and AT2-receptors: conceptual and clinical effects. J. Renin Angiotensin Aldosterone Syst.1(2 Supp. l), S6–S9 (2000).
- The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358, 1547–1559 (2008).
- Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet370, 221–229 (2007).
- Azizi M, Ménard J, Bissery A, Guyene TT, Bura-Rivière A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin. J. Am. Soc. Nephrol.2(5), 947–955 (2007).
- Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation119, 530–537 (2009).
- Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med.358, 2433–2446 (2008).
- Geiger H, Barranco E, Gorostidi M et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J. Clin. Hypertens.6, 324–332 (2009).
- McMurray JJV, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail.1, 17–24 (2008).
- Savergnini SQ, Beiman M, Lautner RQ et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension56(1), 112–120 (2010).
- Takai S, Jin D, Miyazaki M. Targets of chymase inhibitors. Expert Opin. Ther. Targets15(4), 519–527 (2011).
- Steckelings UM, Larhed M, Hallberg A et al. Non-peptide AT2-receptor agonists. Curr. Opin. Pharmacol.11(2), 187–192 (2011).
- Ichihara A, Sakoda M, Kurauchi-Mito A et al. Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings. Hypertens. Res.33(3), 177–180 (2010).